Literature DB >> 22099355

A community-based partnership to promote information infrastructure for bleeding disorders.

Diane J Aschman1, Thomas C Abshire, Amy D Shapiro, Jeanne M Lusher, Ann D Forsberg, Roshni Kulkarni.   

Abstract

Specialists in rare disorders often face challenges in collecting surveillance and research data. As movement toward more fully realizing the potential of electronic health information gains momentum, practitioners who treat individuals with rare disorders are in need of public-private support to tap into the advantages offered by the developing electronic information technologies and the interoperability standards promulgated by the USDHHS. The not-for-profit American Thrombosis and Hemostasis Network (ATHN) was created in 2006 to provide stewardship of a secure, national, web-based database to support federally funded hemophilia treatment centers (HTCs) across the country. In pursuit of its mission to support clinical outcomes analysis, research, advocacy, and public health reporting in the hemostasis and thrombosis community, ATHN has established a spectrum of community-based partnerships. This paper describes the process and public health benefits of creating formal relationships with 127 of the 134 HTCs from 12 regional networks across the U.S., government agencies such as the CDC, Health Resources and Services Administration, and NIH; consumer-based organizations; and industry leaders. This community-based partnership model can be applied to other rare disorders communities with high economic and public health impact.
Copyright © 2011 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22099355     DOI: 10.1016/j.amepre.2011.09.018

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  1 in total

Review 1.  The national haemophilia program standards, evaluation and oversight systems in the United States of America.

Authors:  Mark W Skinner; J Michael Soucie; Kathryn Mclaughlin
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.